I suspect this will most likely become mainstream only when the American federal government is on board.  If patients have a genome (GWAS) in a database that is owed by the VA-Veteran Administration with 'Cloud-like' assess maybe.

Point-of-care genotyping will certainly eliminate the time lag that currently hinders the actionable clinical use of genotyping in cardiovascular disease.

I agree that although the outcome measure is a surrogate marker, there is substantial evidence that it correlates well with clinical outcomes. What needs to be appreciated is that this is only true in those post coronary artery intervention and not in those prescribed clopidogrel for alternate reasons; a fact that has been lost in some recent analyses of the area.

The application of this device brings highly relevant genomic information to the fingertips of practicing cardiologists.

This is a potential game changer!

 The concern here is stent thrombosis and its consequences in all stented patients.  I am optimistic about the contributions genomics and genetic profiling will ultimately make in cardiovascular medicine, but in this instance there is a simpler way--the issue is the final common pathway=high on treatment reactivity on whatever antiplatelet agent the pt is given (not just clopidogrel)in patients undergoing stenting, not just narrowly focussing on genetic variability to CYP2C19 or the fact that clopidogrel is the only drug labelled for elective stenting.   There are patients who have high on treatment reactivity who are clopidogrel responders.  The key in this setting is to simply measure platelet reactivity, for which we have had a cheap simple and unfortunately underused  POC test for some time.